Stocksigma LogoStocksigma Logo

Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets

Marksans Pharma posted strong Q2FY27 operating revenue of ₹940.2 cr, up 30.5% YoY (25% organic), supported by 64.9% growth in UK & Europe and solid US

Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets

Marksans Pharma Ltd · Investor Presentation · 04 Nov 2026, 7:10 pm

Marksans Pharma Delivers Robust Q2FY27 Growth Driven by Core Markets Marksans Pharma posted strong Q2FY27 operating revenue of ₹940.2 cr, up 30.5% YoY (25% organic), supported by 64.9% growth in UK & Europe and solid US traction. EBITDA rose 48.3% YoY to ₹214.3 cr, with margins expanding 274 bps to 22.8% on operating leverage, while PAT reached ₹143.5 cr (+44.8% YoY). H1FY27 operating cash flow surged 4.3x to ₹322 cr, leaving a net cash balance of ₹1,095 cr as of 30th Sep'26. TTM ROCE improved significantly to 24.7%.

Original exchange filing (PDF)

More announcements from Marksans Pharma Ltd

All Marksans Pharma Ltd announcements